10X Capital Podcast
The 10X Capital podcast interviews the world's premier institutional investors to deliver insights on how they manage their capital. Interview topics include investment decision frameworks, capital allocation strategies, GP/LP relationships and many more.
E25: Jeff Galvin, CEO of Addimmune on Finding a Cure for HIV
Jeff Galvin, CEO of Addimmune, sits down with David Weisburd to discuss cell and gene therapy, and how Addimmune is working on a functional solution for HIV.
Key Points
- AGT 103, a gene therapy developed by Jeff Galvin's team, has shown promising results in fighting HIV by modifying the patient's t-cells to resist the virus.
- Gene and cell therapy are revolutionizing medicine by providing potential cures for previously untreatable diseases, such as certain forms of blindness and spinal muscular atrophy.
- The HIV virus is particularly insidious because it integrates its DNA into the host's t-cells, depleting the immune system's ability to fight the virus over time, but new therapies like AGT 103 are showing potential to counteract this mechanism.
We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans.
Chapters
| 0:00 | |
| 2:09 | |
| 2:21 | |
| 8:06 | |
| 11:53 | |
| 12:42 | |
| 16:11 | |
| 20:13 | |
| 23:26 | |
| 25:52 | |
| 28:47 | |
| 30:20 | |
| 31:45 | |
| 34:04 |
Transcript
Loading transcript...
- / -